TRADITIONAL POSTER - ismrm

Poster Sessions
1931. Molecular Susceptibility Contrast MRI of Tumor Angiogenesis with Targeted Iron Oxide
Nanoparticles
Martijn Wolters 1,2 , Marlies Oostendorp 1,3 , Bram F. Coolen 2 , Mark J. Post 3,4 , Gustav J. Strijkers 2 , Klaas
Nicolay 2 , Walter H. Backes 1,3
1 Department of Radiology, Maastricht University Medical Center, Maastricht, Netherlands; 2 Biomedical NMR, Department of
Biomedical Engineering, Eindhoven University of Technology, Eindhoven, Netherlands; 3 Cardiovascular Research Institute
Maastricht (CARIM), Maastricht University Medical Center, Maastricht, Netherlands; 4 Department of Physiology, Maastricht
University, Maastricht, Netherlands
The purpose of this study was to evaluate Susceptibility Gradient Mapping (SGM) for molecular MRI to selectively detect tumor angiogenesis in mice with
cNGR-labeled SPIOs. SGM is a positive contrast technique to detect susceptibility effects of SPIOs. In this experimental study we found CNR values for
SGM comparable to gradient echo (GE) images. Furthermore, a trend towards stronger contrast enhancement for targeted SPIOs compared with untargeted
SPIO was perceived.
1932. MR Imaging of Angiogenesis in Tumor Xenografts by α vβ 3 - Targeted Magnetofluorescent Micellar
Nanoprobes
Chase W. Kessinger 1 , Chalermchai Khemtong 1 , Osamu Togao 1 , Masaya Takahashi 1 , Jinming Gao 1
1 UT Southwestern Medical Center, Dallas, TX, United States
Here we report the use of αvβ3- targeted magnetofluorescent micellar nanoprobes that allowed detection of angiogenic tumor vessels by both fluorescent and
magnetic resonance imaging methods. The αvβ3-targeting specificity and temporal tumor accumulation profiles were demonstrated in a human lung tumor
xenograft model in nude mice using 3D gradient echo sequences and T2* - weighted dynamic contrast enhancement MRI over one hour.
1933. Lectinized Liposomes for Multimodal in Vivo Molecular Imaging of the Tumor Endothelium
Arvind P. Pathak 1 , Yoshinori Kato 1 , Nicole Benoit 1
1 JHU ICMIC Program, Russel H. Morgan Dept. of Radiology and Radiological Science, The Johns Hopkins University School of
Medicine, Baltimore, MD, United States
Here we describe the development of dual contrast lectinized liposomes that improve our ability to image the structural and functional changes in tumor
blood vessels using MRI and optical imaging. Limitations of conventional contrast-enhanced in vivo MRI include low spatial resolution because of
relatively short circulation half-life of such agents, and loss of contrast due to extravasation from permeable tumor vessels. We developed a blood vesselspecific
nanoparticle targeted to Bandeiraea Simplicifolia lectin, a carbohydrate-binding protein that binds to α-D-galactosyl residues on endothelial cells.
MRI and optical imaging demonstrate that multi-modal, targeted liposomes greatly enhance our ability to characterize tumor angiogenesis.
1934. Quantitative Molecular Imaging of Atherosclerotic Endothelial Dysfunction with Perfluorocarbon
(19F) Nanoparticle Magnetic Resonance Imaging and Spectroscopy
Lei Zhang 1 , Huiying Zhang 1 , Kristin Bibee 1 , Stacy Allen 1 , Junjie Chen 1 , Gregory M. Lanza 1 , Samuel A.
Wickline 1
1 Washington University School of Medicine, St. Louis, MO, United States
Disturbed endothelial barrier function in atherosclerosis has been detected by MRI by imaging gadolinium leakage into the vascular interstitium but not yet
quantified. Alternatively, we propose that the unique, no background 19F signal from crown ether perfluorocarbon-core nanoparticles (NP: ~250 nm) might
both visualize and quantify endothelial disruption in advanced atherosclerosis.For both advanced experimental atherosclerosis and native human
atherosclerosis tissues, nontargeted NP rapidly penetrate the leaky endothelial barrier, which can be visualized and quantified ex vivo with the use of ¡°no
background¡± 19F MRI and MRS. This experimental strategy offers a potential new approach for quantification of endothelial dysfunction employing both
in vivo and ex vivo incubation with nanoparticle tracers.
1935. MRI-Guided Fluorescence Imaging of Glial Reactivity in Chronic Neuropathic Pain
Scott C. Davis 1 , Lisa H. Treat, 12 , Edgar Alfonso Romero-Sandoval 2,3 , Kimberley S. Samkoe 1 , Brian W.
Pogue 1 , Joyce A. DeLeo 2,3
1 Thayer School of Engineering, Dartmouth College, Hanover, NH, United States; 2 Department of Anesthesiology, Dartmouth College,
Hanover, NH, United States; 3 Department of Pharmacology and Toxicology, Dartmouth College, Hanover, NH, United States
Glial reactivity plays an important role in the biochemical processes associated with acute and chronic pain and neurodegenerative diseases such as
Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. This study demonstrates the potential to image Glial Fibrillary Acidic Protein (GFAP)
expression in the brains of rats after peripheral nerve injury using MR-guided fluorescence molecular tomography (MRg-FMT). MRg-FMT images showed
elevated GFAP expression in the brains of injured animals, indicating enhanced astrocytic reactivity as compared to control animals. Quantitative imaging
of glial reactivity in vivo would be an important innovation for investigating and deploying new treatment strategies that target glial mechanisms.
1936. MR Molecular Imaging of HER-2 in a Murine Tumor Xenograft by SPIO Labeling of Anti-HER-2
Affibody.
Manabu Kinoshita 1 , Yoshichika Yoshioka 2 , Yoshiko Okita 1 , Naoya Hashimoto 1 , Toshiki Yoshimine 1
1 Department of Neurosurgery, Osaka University Medical School, Suita, Osaka, Japan; 2 High Performance Bioimaging Research
Facility, Osaka University, Graduate School of Frontier Biosciences, Suita, Osaka, Japan
In vivo molecular imaging is a rapidly growing research area both for basic and clinical science. Non-invasive imaging of in vivo conditions in a molecular
level will help understand the biological characteristics of normal and diseased tissues without performing surgical invasive procedures. Among various
imaging modalities, magnetic resonance imaging (MRI) has gained interest as a molecular imaging modality for its high special resolution. In this research,
we have demonstrated that the combined use of HER-2 targeting Affibody, a small 7kDa molecule that behaves similarly to antibodies, and